AbbVie (ABBV)
(Delayed Data from NYSE)
$195.45 USD
-1.37 (-0.70%)
Updated Oct 3, 2024 04:00 PM ET
Pre-Market: $195.00 -0.45 (-0.23%) 9:12 AM ET
3-Hold of 5 3
C Value D Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$195.45 USD
-1.37 (-0.70%)
Updated Oct 3, 2024 04:00 PM ET
Pre-Market: $195.00 -0.45 (-0.23%) 9:12 AM ET
3-Hold of 5 3
C Value D Growth F Momentum D VGM
Zacks News
AbbVie (ABBV) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
AbbVie (ABBV) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Karyopharm's (KPTI) Eltanexor Gets Orphan Drug Tag for MDS
by Zacks Equity Research
The FDA bestows an Orphan Drug status to Karyopharm's (KPTI) investigational candidate, eltanexor, for treating myelodysplastic syndromes.
J&J (JNJ) Q4 Earnings Beat Estimates by a Penny, Sales Miss
by Zacks Equity Research
J&J (JNJ) reports mixed fourth-quarter results. It beats estimates for earnings but misses the same for sales.
Johnson & Johnson (JNJ) Surpasses Q4 Earnings Estimates
by Zacks Equity Research
Johnson & Johnson (JNJ) delivered earnings and revenue surprises of 0.47% and 1.77%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
AbbVie (ABBV) Gains But Lags Market: What You Should Know
by Zacks Equity Research
AbbVie (ABBV) closed at $132.16 in the latest trading session, marking a +0.14% move from the prior day.
AbbVie's (ABBV) Skyrizi Gets FDA Nod for Psoriatic Arthritis
by Zacks Equity Research
AbbVie (ABBV) secures approval in the United States for Skyrizi to treat adult patients with active psoriatic arthritis.
Pharma Stock Roundup: GSK's Consumer Unit Offer Rejection, FDA Updates for AZN, PFE
by Kinjel Shah
Glaxo (GSK) rejects a $68 billion buyout offer for its consumer healthcare unit from Unilever. FDA updates for Pfizer (PFE), AbbVie (ABBV) and AstraZeneca (AZN) grab headlines.
J&J (JNJ) to Set the Stage for Pharma Sector Q4 Earnings
by Zacks Equity Research
J&J's (JNJ) Pharma segment is expected to have performed above the market. It remains to be seen if sales improved in the Medical Devices segment in the fourth quarter.
Zacks Value Trader Highlights: AbbVie, The Andersons and Ingredion
by Zacks Equity Research
AbbVie, The Andersons and Ingredion are highlighted in this Zacks Value Traders article.
3 Value Stocks Breaking out in 2022
by Tracey Ryniec
Not all stocks are selling off to start 2022. These cheap, top Zacks Ranked stocks are doing the opposite.
Zacks Industry Outlook Highlights: Roche, Pfizer, AbbVie and Merck
by Zacks Equity Research
Roche, Pfizer, AbbVie and Merck are highlighted in this Industry Outlook article.
AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, AbbVie (ABBV) closed at $135.87, marking a +1.76% move from the previous day.
AbbVie's (ABBV) Rinvoq Gets FDA Nod for Atopic Dermatitis
by Zacks Equity Research
FDA approves AbbVie's (ABBV) Rinvoq for the treatment of moderate to severe atopic dermatitis in adults and children aged 12 and above. This is the third indication for Rinvoq in the United States.
Pfizer's (PFE) Cibinqo Gets FDA Nod for Atopic Dermatitis
by Zacks Equity Research
After a series of delays, Pfizer's (PFE) oral JAK inhibitor, Cibinqo (abrocitinib), gets approval for treating adults with atopic dermatitis in the United States.
4 Large-Cap Drugmaker Stocks to Watch Despite Omicron Woes
by Kinjel Shah
Drug/biotech and medical device companies are likely to remain in the spotlight in 2022. Among the large drugmakers Roche (RHHBY), Pfizer (PFE), AbbVie (ABBV), and Merck (MRK) are worth retaining in your portfolio.
The Zacks Analyst Blog Highlights: Pfizer (PFE), Beam Therapeutics, AbbVie, Merck and Glaxo
by Zacks Equity Research
Pfizer (PFE), Beam Therapeutics, AbbVie, Merck and Glaxo are highlighted in this analyst blog article.
Pharma Stock Roundup: PFE's Research Deal With BEAM & Other Updates
by Kinjel Shah
Pfizer (PFE) inks research collaboration with Beam Therapeutics. Merck's (MRK) Keytruda improves survival in adjuvant lung cancer
Pfizer's (PFE) Prevnar 20 Plus COVID Vaccine Study Succeeds
by Zacks Equity Research
Pfizer's (PFE) data from a phase III study showed that its COVID-19 vaccine and pneumococcal conjugate vaccine, Prevnar-20 can be given at the same time.
Merck (MRK) Keytruda Betters Survival in Adjuvant Lung Cancer
by Zacks Equity Research
Merck's (MRK) phase III study evaluating Keytruda for adjuvant stage IB-IIIA non-small cell lung cancer (NSCLC) meets one of its dual primary endpoints of disease-free survival (DFS).
Pfizer (PFE) Partners Beam Therapeutics for Rare Disease Drugs
by Zacks Equity Research
Pfizer (PFE) collaborates with Beam Therapeutics (BEAM) to advance the next generation of gene-editing therapies.
AbbVie (ABBV) Gains As Market Dips: What You Should Know
by Zacks Equity Research
AbbVie (ABBV) closed at $136.39 in the latest trading session, marking a +1.12% move from the prior day.
AstraZeneca (AZN) Inks Deal to Develop ATTR-CM Candidate
by Zacks Equity Research
AstraZeneca (AZN) inks collaboration and license agreement with Neurimmune AG to develop/commercialize the latter's NI006 for treating transthyretin amyloid cardiomyopathy.
Sanofi (SNY) Inks Deal to Develop AI-Driven Precision Medicines
by Zacks Equity Research
Sanofi (SNY) signs a collaboration agreement with Exscientia to develop precision-engineered medicines in oncology and immunology using the latter's AI-driven platform.
The Zacks Analyst Blog Highlights: Pfizer, AbbVie, Eli Lilly and J&J
by Zacks Equity Research
Pfizer, AbbVie, Eli Lilly and J&J are included in this analyst blog.
AbbVie (ABBV) Seeks Rinvoq Nod for Non-Radiographic AS
by Zacks Equity Research
AbbVie's (ABBV) application seeking approval of Rinvoq for nr-axSpA was based on data from the phase III SELECT-AXIS 2 (Study 2) study.